Oragenics (OGEN) Net Equity Issued and Repurchased (2010 - 2026)
Oragenics' (OGEN) quarterly Net Equity Issued and Repurchased came in at $79210.0 in Q1 2026, down 96.99% YoY from $2.6 million in Q1 2025, and up 7048.25% on a QoQ basis from -$1140.0 in Q4 2025.
Oragenics (OGEN) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 11 years of Net Equity Issued and Repurchased data on file, last reported at $79210.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 96.99% year-over-year to $79210.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78070.0 (down 98.95% YoY) and the FY2025 annual result came in at $2.6 million, down 60.52% from the prior year.
- Net Equity Issued and Repurchased rose to $79210.0 in Q1 2026, from -$1140.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $3.9 million in Q3 2024 to a low of -$1140.0 in Q4 2025.
- A 4-year average of $1.2 million and a median of $513605.5 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 43.33% in 2025, down 157.87% in 2025.
- Tracing OGEN's Net Equity Issued and Repurchased over 4 years: stood at $72000.0 in 2022, then tumbled by 97.26% to $1970.0 in 2024, then sank by 157.87% to -$1140.0 in 2025, then soared by 7048.25% to $79210.0 in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $79210.0 (Q1 2026), -$1140.0 (Q4 2025), and $2.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,210.00 |
| Mar 31, 2026 | 79,210.00 |
| Dec 31, 2025 | -1,140.00 |
| Dec 31, 2025 | -1,140.00 |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 1,970.00 |
| Dec 31, 2024 | 1,970.00 |
| Sep 30, 2024 | 3.88 Mn |
| Sep 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 948,001.00 |
| Jun 30, 2024 | 948,001.00 |
| Mar 31, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2022 | 72,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Jun 30, 2021 | 27.80 Mn |
| Jun 30, 2021 | 27.80 Mn |
| Mar 31, 2021 | 27.80 Mn |
| Mar 31, 2021 | 27.80 Mn |